Home/Pipeline/Aprocitentan

Aprocitentan

Resistant Hypertension

ApprovedLaunch Phase

Key Facts

Indication
Resistant Hypertension
Phase
Approved
Status
Launch Phase
Company

About Johnson & Johnson

Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.

View full company profile

Other Resistant Hypertension Drugs

DrugCompanyPhase
Barostim™CVRxCE Mark
Firibastat (QGC001)Quantum GenomicsPhase 3
DirectAblate Renal Denervation SystemSymple SurgicalPre-clinical
BaxdrostatAstraZenecaPhase III
TRYVIO/JERAYGO (aprocitentan)IdorsiaMarketed